Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells
Open accessThe DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Abstract
The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Molecular pathways and cellular interactions involved in HSC activation and deactivation. Activated HSCs are the main effector cells during hepatic fibrosis. In the healthy liver, they metabolize and store retinoids. Upon activation by fibrogenic stimuli, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate α-smooth muscle actin (αSMA), and produce collagen I. Various factors, including immune cell-derived fibrogenic molecules, growth factors, and lipopolysaccharide, as well as profibrotic lipid mediators such as lysophosphatidylinositol and lysophosphatidic acid, induce HSC activation in the course of chronic liver disease. TGF-β is the most HSC potent activator, which is produced by infiltrating lymphocytes and monocytes, Kupffer cells (KCs), and damaged hepatocytes. IL-17, produced by neutrophils and Th17 cells, sensitizes HSCs to TGF-β by upregulating TGF-β receptor II (TGF-βRII). In addition, platelet-derived growth factor (PDGF), which is produced by endothelial cells and macrophages, further promotes HSC activation. During fibrosis resolution, HSCs either die or revert to an inactive state by upregulating transcription factors such as peroxisome proliferator-activated receptor-γ (PPARγ), GATA-binding factor 4 (GATA4), GATA6, and transcription factor 21 (TCF21). NK and CD8+ T cells can eliminate activated HSCs by inducing apoptosis (Further abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; HH, hedgehog ligands; IHH, Indian Hedgehog; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; LPS, lipopolysaccharide; miRNA, microRNA; MSR1, macrophage scavenger receptor 1; NF-κB, nuclear factor κ-light chain-enhancer of activated B cells; OPN, osteopontin; oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; SHH, sonic hedgehog; TLR4, Toll-like receptor 4). Modified from reference [5].](https://figures.cochat.ai/paper-figures/ba56d748dfcc4395a6907c0c93306af8/liver-fibrosis-from-basic-science-towards-clinical-progress-focusing-on-the-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A pivotal element in acute and chronic liver damage is hepatic stellate cells (HSCs) activation. In response to hepatocyte injury, HSCs transition into activated myofibroblasts, overproducing extracellular matrix components and driving fibrosis (Akkız H, 2024).”
From A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis (2026) · cites this paper as Akkız H, 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–224 of 224
Kaur, S., Tripathi, D. M., Dongre, K., Garg, V., Rooge, S. B., Mukopadhyay, A., Sakhuja, P., & Sarin, S. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.016 · Cited by 45 · cited 1×
“In addition to LSECs, endothelial progenitor cells (EPCs), i.e., bone marrow-derived endothelial cells, also contribute to intrahepatic angiogenesis [129,130].”
BackgroundEpigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
Claveria-Cabello, A., Colyn, L., Arechederra, M., Urman, J. M., Berasain, C., Avila, M. A., & Fernandez-Barrena, M. G. (2020) · Cells · doi:10.3390/cells9102321 · Cited by 43 · cited 3×
“MiRNAs are single-stranded noncoding RNAs containing about 18–25 nucleotides and drive post-transcriptional gene expression through altering mRNA degradation [163]; they display either profibrotic or antifibrotic effects [162,163].”
BackgroundInnate lymphoid cells in organ fibrosis
Mikami, Y., Takada, Y., Hagihara, Y., & Kanai∥, T. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.07.002 · Cited by 41
Meyer, J., Balaphas, A., Fontana, P., Morel, P., Robson, S. C., Sadoul, K., Gonelle‐Gispert, C., & Bühler, L. H. (2020) · Cells · doi:10.3390/cells9051243 · Cited by 41 · cited 5×
“LSECs actively participate in the clearance of antigens reaching the liver sinusoids and contribute to the perpetuation of the tolerogenic state [116,117].”
BackgroundInfluentialNovel insights into dendritic cells in the pathogenesis of systemic sclerosis
Carvalheiro, T., Zimmermann, M., Radstake, T. R. D. J., & Marut, W. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13417 · Cited by 40 · cited 2×
“CCl 4 -induced liver fibrosis is more pronounced in HBV-transgenic mice as opposed to wild-type mice [139].”
BackgroundLncRNA H19-EZH2 interaction promotes liver fibrosis via reprogramming H3K27me3 profiles
Li, X., Zhou, F., Li, Y., Xue, X., Qu, J., Fan, G., Liu, J., Sun, R., Wu, J., Zheng, Q., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01145-z · Cited by 40 · cited 1×
“…2 knockout (Mdr2 -/- ) mice, cholangiocyte-derived exosomal H19 is transferred to adjacent hepatocytes and HSCs, which propels the progression of cholestatic liver fibrosis by modulating bile acid accumulation in hepatocytes and promotes the activation and proliferation of HSCs [165,166].”
BackgroundInflammation and TGFβ1: Lessons from the TGFβ1 null mouse
Kulkarni, A. B., & Karlsson, S. (1997) · Research in Immunology · doi:10.1016/s0923-2494(97)82669-7 · Cited by 38
Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease
Liedtke, C., Nevzorova, Y. A., Luedde, T., Zimmermann, H., Kroy, D., Strnad, P., Berres, M.-L., Bernhagen, J., Tacke, F., Nattermann, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.814496 · Cited by 37 · cited 7×
“Recently, this classification has been revised, and two novel members have been added to the ILC family, which are conventional NK (NK) cells and lymphoid tissue-inducer cells [134].”
BackgroundInfluentialFibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
Subramanian, P., Hampe, J., Tacke, F., & Chavakis, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136996 · Cited by 37 · cited 1×
“…growth factors, and distinct signals, including cell–cell contact with macrophages, cytokines derived from activated immune cells, and pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs), mediate the activation of HSCs during liver injury [2–5, 14,15].”
BackgroundSmad2 increases the apoptosis of activated human hepatic stellate cells induced by TRAIL
Xu, F., Zhou, D., Meng, X., Wang, X., Liu, C., Huang, C., Li, J., & Zhang, L. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.01.013 · Cited by 36 · cited 2×
“In contrast, successful antiviral treatment in patients with chronic viral hepatitis or with considerable lifestyle changes in NASH patients modulate the resolution of fibrosis [6–9].”
BackgroundResultThe Bone Marrow and Liver Fibrosis: Friend or Foe?
Kallis, Y. N., & Forbes, S. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.026 · Cited by 28 · cited 1×
“Potential other sources of hepatic myofibroblasts in the pathogenesis of liver fibrosis might include epithelial-to-mesenchymal transition (EMT) [46], but, at least in mice, cell fate mapping studies excluded EMT from the pathogenesis of liver fibrosis [47–51].”
BackgroundCholestasis and cholestatic syndromes
Hirschfield, G. M., & Heathcote, E. J. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32832914b4 · Cited by 27 · cited 1×
“Cholestatic injury occurs as a result of stasis in the bile flow, such as in primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and biliary atresia [12].”
BackgroundYu, X., Elfimova, N., Müller, M., Bachurski, D., Koitzsch, U., Drebber, U., Mahabir, E., Hansen, H. P., Friedman, S. L., Klein, S., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.013 · Cited by 27 · cited 1×
“However, activated HSCs can be discerned into several subsets [2–5, 19, 20].”
BackgroundGoddard, C., Smith, A., Hoyland, J. A., Baird, P., McMahon, R. F., Freemont, A. J., Shomaf, M. S., Haboubi, N. Y., & Warnes, T. W. (1998) · Gut · doi:10.1136/gut.43.3.433 · Cited by 25 · cited 2×
“Studies on the origin of hepatic myofibroblasts have documented their heterogenous derivation, which inter alia includes HSCs, portal fibroblasts, and bone marrow-derived cells such as fibrocytes and mesenchymal stem cells [40–42].”
BackgroundPiedade, J., Pereira, G., Guimarães, L., Duarte, J., Victor, L., Baldin, C., Inacio, C., dos Santos, R. R., Chaves, Ú., Nunes, E. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91099-1 · Cited by 21
Current Therapy of Chronic Viral Hepatitis B, C and D
Schlaak, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060964 · Cited by 20 · cited 1×
“Still, better therapeutic strategies are currently being developed [218–220].”
BackgroundThe Mechanisms of HSC Activation and Epigenetic Regulation of HSCs Phenotypes
Page, A., Mann, D. A., & Mann, J. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-014-0052-0 · Cited by 17 · cited 1×
“MeCP2-deficient mice displayed attenuation of the expression of fibrogenic markers such as collagen-1, TIMP-1, and α -SMA and regression of liver fibrosis after CCl 4 treatment [177].”
BackgroundEndothelial progenitor cells in cirrhosis: The more, the merrier?
Rautou, P.-E. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.001 · Cited by 13 · cited 3×
“Importantly, endothelial dysfunction occurs early in chronic liver disease, even before the onset of fibrosis and inflammation [131].”
BackgroundInfluentialDNA methylation controls liver fibrogenesis
Liu, X., & Brenner, D. A. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.16 · Cited by 13 · cited 8×
“The researchers also investigated the production of DNA methyltransferases (DNMT1, 3a, and 3b) orchestrating the annotation of 5-mC and methylcytosine dioxygenase (TET) that oxidize 5-mC to 5-hmC [168].”
BackgroundInfluentialShi, C., Wang, Y., Jiao, F., Chen, Q., Cao, P., Pei, M., Zhang, L., Guo, J., Deng, W., Wang, L.-W., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.683526 · Cited by 12 · cited 9×
“Experimental studies identified several profibrogenic miRNAs, including miR-21, miR-221, miR-222, and miR-27 [162,163].”
BackgroundInfluentialImplication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less
Lucantoni, F., Benedicto, A. M., Gruevska, A., Moragrega, Á. B., Fuster‐Martínez, I., Esplugues, J. V., Blas‐García, A., & Apostolova, N. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04789-7 · Cited by 12 · cited 1×
“In experimental mouse models of CCl 4 -induced liver fibrosis, autophagy-related protein 7 (ATG7), fibrogenesis, and ECM accumulation were found to be remarkably reduced, but this finding could not be replicated in cultured HSCs by adding exogenous fatty acids [156].”
BackgroundOh, J. H., Park, Y., Goh, M. J., Sinn, D. H., Ahn, S. B., Kang, W., Gwak, G., Paik, Y., Choi, M. S., Lee, J. H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36668-2 · Cited by 7 · cited 1×
“…a recent study of 911 patients with HBV-related compensated cirrhosis who received antiviral treatment with entecavir or tenofovir showed a regression of liver fibrosis [i.e., improvement in the Fibrosis 4 Index (FIB-4) from the first year of treatment] and a lower risk of developing HCC [223].”
BackgroundPaving the TRAIL to anti‐fibrotic therapy
Guicciardi, M. E., & Gores, G. J. (2016) · Hepatology · doi:10.1002/hep.28520 · Cited by 5 · cited 8×
“Of five TRAIL receptors currently documented in humans, TRAIL-R1/DR4 and TRAIL-R2/DR5 trigger apo ptosis [188].”
BackgroundInfluentialWill inhibition of cellular crosstalk resolve liver fibrosis?
Harris, E. N. (2022) · Hepatology · doi:10.1002/hep.32361 · Cited by 1 · cited 3×
“Almost half of the activated HSCs died after ceasing CCl 4 -dependent liver injury [198–200].”
Background
Cited by
Tauil, R. B., Golono, P. T., de Lima, E. P., Goulart, R. D. Á., Guiguer, É. L., Bechara, M. D., Nicolau, C. C. T., Yanaguizawa, J. L., Fiorini, A. M. R., Méndez‐Sánchez, N., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101354 · Cited by 85
Giangregorio, F., Mosconi, E., Debellis, M. G., Provini, S., Esposito, C., Garolfi, M., Oraka, S., KALOUDI, O., Mustafazade, G., Marín‐Baselga, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195880 · Cited by 79
“However, not all healthcare institutions have access to advanced imaging technologies like VCTE or MRE.”
BackgroundPuri, M., & Sonawane, S. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093988 · Cited by 41
“Furthermore, LSECs themselves become more susceptible to the effects of TGF-β , which contributes to their capillarization and loss of normal function [42].”
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“Conversely, hypomethylation of pro-fibrotic genes like TGF β 1 promotes sustained fibrogenic signaling, leading to continuous HSC activation and excessive ECM production [49–51].”
Metadata
- Authors
- Akkız, H., Gieseler, R. K., & Canbay, A.
- Affiliations
- Bahçeşehir University (TR)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Corresponding author
- Akkız, Hikmet
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-07-18
- Volume
- 25
- Issue
- 14
- Pages
- 7873
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11277292
- OpenAlex
- W4400775597
- Semantic Scholar
- 8810ad06f0650b984f245dec696c68e2f2723093
- Cited by
- 191
- References
- 223
- Citations by year
- 2026: 112 · 2025: 70 · 2024: 9
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cells, hepatic fibrogenesis, myofibroblast transdifferentiation, extracellular matrix deposition, hepatic stellate cell activation, HSC heterogeneity, macrophages, hepatocyte death, liver inflammation, antifibrotic therapy, cirrhosis reversal, cellular stress response, cytokines and chemokines
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Hepatic Stellate Cells, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.